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Construction of the Ara-lacS reporter plasmids and tf55α-lacS reporter 
plasmids and transformation in Sso strains 
The Sso strains PH1-16(pMJ05-Ara/tf55-lacS-3’UTR), PH1-16(pMJ05-Ara/tf55-lacS-
2194-RBM-3’UTR), PH1-16(pMJ05-Ara/tf55-lacS-2194-3’UTR) and PH1-16(pMJ05- 
Ara/tf55-∆2194-RBM-2194-3’UTR) were generated as follows.  
Plasmid pMJ05-Ara-lacS-3´UTR: The Sso shuttle plasmid pMJ05 harboring 
the SSO3019/lacS gene preceded by the tf55α-Promoter was provided by S.V Albers 
(pMJ05-tf55α-lacS-lacS-3’UTR). The Sso shuttle plasmid pMJ05 containing the lacS 
gene preceded by the Ara-promoter was generated as follows. The fragment Ara-
lacS-lacS-3’UTR of plasmid pSAV5 (29) was isolated after EagI/AvrII cleavage, and 
inserted into the corresponding sites of pMJ05, resulting in plasmid pMJ05-Ara-lacS-
3´UTR. 
 Plasmid pMJ05-Ara-lacS-2194-RBM- 3´UTR: The 2194-RBM sequence was 
inserted into pMJ05-Ara-lacS-lacS-3´UTR using overlap PCR. First, the sub-
sequence 5´-TCAAGTCTCACTATACCAAA-3´ in the lacS-3´ UTR present in pSAV5 
(29) was replaced by the 2194-RBM (5´-GGAGATATAGTAGGTATAGTA-3´; lacS 
2194-RBM-3’UTR). The overlap PCR was performed using the oligonucleotides 5’- 
ccggCCTAGGGCACCATATGTTTAG-3’ containing an AvrII site (underlined) together 
with 5´-TACTATACCTACTATATCTCCGAAAGTGGGGCCCCTTAG-3´ and 
oligonucleotides 5´-GGAGATATAGTAGGTATAGTATGAGTTTTCTTTTAATCTT-
ATTC-3´ together with 5´-GAAGCGAGAAGAATCATAATGG-3´ and pSAV5 as 
template. The second PCR was performed using the annealed PCR products as 
template together with oligonucleotides 5´-ccggCCTAGGGCACCATATGTTTAG-3´ 
containing an AvrII restriction site (underlined) and 5´-
GAAGCGAGAAGAATCATAATGG-3´, which binds 3´ of the EagI site present in the 
template. The PCR product Ara-lacS-2194-RBM-3´UTR was cleaved with AvrII and 
EagI and ligated into the corresponding sites of plasmid pMJ05 (29), giving rise to 
plasmid pMJ05-Ara-lacS-2194-RBM-lacS-3´UTR.  
 
Plasmid pMJ05-Ara-lacS-2912-RBM- 3´UTR and plasmid pMJ05-Ara-lacS-
1742-RBM- 3´UTR: 
The 2912-RBM and 1742-RBM sequences, respectively, were inserted into 
plasmid pMJ05-Ara-lacS-lacS-3´UTR using overlap PCR. First, the sub-sequence 5´-
TCAAGTCTCACTATACCAAA-3´ in the lacS-3´ UTR present in pSAV5 (29) was 
replaced by the 2912-RBM (5´-GGAAGTATTGGGAGGAATGAA-3´; lacS 2912-RBM-
3’UTR) and the 1742-RBM (5´- GGATGGATATTAGGTACTGGG -3´; lacS 1742-
RBM-3’UTR), respectively. The overlap PCR for 2912-RBM insertion was performed 
using the oligonucleotides 5’- ccggCCTAGGGCACCATATGTTTAG-3’ containing an 
AvrII site (underlined) together with 5´- 
GGAAGTATTGGGAGGAATGAAGTATGAGTTTTCTTTTAATCTTATTC-3´ and 
oligonucleotides 5´- TTCATTCCTCCCAATACTTCCGAAAGTGGGGCCCCTTAG -3´ 
together with 5´-GAAGCGAGAAGAATCATAATGG-3´ and pSAV5 as template. The 
overlap PCR for 1742-RBM insertion was performed using the oligonucleotides 5’- 
ccggCCTAGGGCACCATATGTTTAG-3’ containing an AvrII site (underlined) together 
with 5´-GGATGGATATTAGGTACTGGGGTATGAGTTTTCTTTTAATCTTATTC -3´ 
and oligonucleotides 5´-CCCAGTACCTAATATCCATCCGAAAGTGGGGCCCCTTAG 
-3´ together with 5´-GAAGCGAGAAGAATCATAATGG-3´ and pSAV5 as template.  
The second PCR was performed using the annealed PCR products as 
template together with oligonucleotides 5´-ccggCCTAGGGCACCATATGTTTAG-3´ 
containing an AvrII restriction site (underlined) and 5´-
GAAGCGAGAAGAATCATAATGG-3´, which binds 3´ of the EagI site present in the 
template. The PCR products Ara-lacS-2912-RBM-3´UTR and Ara-lacS-1742-RBM-
3´UTR was cleaved with AvrII and EagI and ligated into the corresponding sites of 
plasmid pMJ05 (29), giving rise to plasmids pMJ05-Ara-lacS-2912-RBM-lacS-3´UTR 
and pMJ05-Ara-lacS-1742-RBM-lacS-3´UTR, respectively. 
 
Plasmid pMJ05-tf55α-lacS-2194-RBM-3’UTR: As described above, the Ara-
lacS-2194-RBM-3´UTR generated by overlap-PCR was cleaved with NcoI and EagI 
to remove the Ara promoter. The fragment lacS-2194-RBM-3´UTR was then ligated 
into the corresponding sites of plasmid pSAV11 (29), resulting in plasmid pSAV11-
tf55α-lacS-2194-RBM-3’UTR. The tf55α-lacS-2194-RBM-3’UTR was finally cloned 
into the AvrII and EagI sites of plasmid pMJ05 (29), resulting in plasmid pMJ05-tf55α-
lacS-2194-RBM-lacS-3´UTR.  
Plasmids pMJ05-Ara-lacS-2194-3´UTR and pMJ05-tf55α-lacS-2194-3´UTR: 
To generate the lacS-2194-3´UTR reporter constructs, 250 nt of the 2194-3´UTR 
(coordinates: 2017993-2018243) were PCR amplified using the oligonucleotides 5´-
ccggGGGCCCTTATATATTTGGAGGTAGTAAG-3´ containing an ApaI restriction site 
(underlined) and 5´-ggccCGGCCGGAGGTGGAACCTCAACAG-3´ containing an 
EagI restriction site (underlined). The PCR product was cleaved with ApaI and EagI, 
and then inserted into the corresponding restriction sites of plasmid pSAV5, 
containing the Ara-promoter, and of pSAV11, containing the tf55α-promoter, 
respectively, resulting in plasmids pSAV5/pSAV11-lacS-2194-3’UTR. The respective 
AvrII-EagI fragments were reisolated from the latter plasmids and inserted into 
plasmid pMJ05 cleaved with the same enzymes (loss of the tf55α-promoter), 
resulting in plasmids pMJ05-Ara-lacS-2194-3´UTR and pMJ05- tf55α-lacS-2194-
3´UTR, respectively.  
Plasmid pMJ05-tf55α-lacS-∆2194-RBM-2194-3‘UTR: The replacement of the 2194-
RBM in plasmid pMJ05-tf55α-lacS-2194-3´UTR was generated by overlap PCR. The 
overlap PCR was performed using the template pSAV5 lacS-2194-3’UTR, containing 
the Ara-promoter, together with the oligonucleotide pair 5´-
ccggCCTAGGGCACCATATGTTTAG-3´ (AvrII restriction site is underlined) and 5´-
GCGATGGTATGGTGGGCCAGAATATGCTTATAGCCAAATCTTAC-3´ as well as 
the oligonucleotide pair 5´-TTCTGGCCCACCATACCATCGC-
TTTCTTATCATTATAATAATCAT-3´ and 5´-GAAGCGAGAAGAATCATAATGG-3´, 
which binds 3´ of the EagI site present in the template. The second PCR was 
performed using the annealed PCR products as template together with the 
oligonucleotides 5’-ccggCCTAGGGCACCATATGTTTAG-3’ (AvrII restriction site is 
underlined) and 5´-GAAGCGAGAAGAATCATAATGG-3´, which binds 3´ of the EagI 
site present in the template. The PCR product was cleaved with AvrII and EagI and 
ligated into the corresponding sites of plasmid pMJ05, resulting in plasmid pMJ05-
Ara-lacS-∆2194-RBM-2194-3’UTR. In addition, the PCR product was cleaved with 
ApaI and EagI and cloned into the corresponding sites of plasmid pSAV11, resulting 
in plasmid pSAV11-lacS-∆2194-RBM-2194-3´UTR. The latter plasmid was cleaved 
with AvrII and EagI and the corresponding fragment was inserted into the AvrII and 
EagI sites of plasmid pMJ05, resulting in plasmid pMJ05-tf55α-lacS-∆2194-RBM-
2194-3´UTR.  
The pSAV5-and pSAV11 constructs were transformed into E. coli Top10 
(Thermo Fisher scientific). The transformed cells were grown on LB-plates 
supplemented with 100 µg/ml ampicillin at 37°C. The ligated pMJ05 derivatives were 
transformed in E. coli Top10 and the transformed cells were grown on LB-plates 
containing 50 µg/ml ampicillin at 20°C. All constructed plasmids were verified by 
restriction digests and the corresponding inserts were validated by DNA sequencing.  
All Sso shuttle plasmids were transformed by electroporation in Sso PH1-16 (∆pyrEF; 
∆lacS), and the selection of plasmid bearing cells was performed as described (29).  
Genomic DNA was isolated from the corresponding strains and the correct insertion 
of the respective DNA fragments was confirmed by PCR using the oligonucleotides 
5´-GGATGCTAAACAACTATTCAAACTG-3´ and 5´-
GTTGTGTGGAATTGTGAGCGGATAA-3´ followed by DNA sequencing of the PCR-
products. 
 
Analytical size-exclusion chromatography  
Analytical size-exclusion chromatography (ASEC) was performed with a Superdex 
S200 10/300 GL column (GE Healthcare) equilibrated in buffer containing 20 mM 
HEPES (pH 7.5),150 mM NaCl, 1 mM β-mercaptoethanol and 5 mM MgCl2.  ASEC 
was carried out at 20°C with a flow rate of 0.5 ml/min using a HPLC device (Agilent 
Technologies 1260 infinity). 50 µl of the SmAP2-RBM (72 pmol/µl) and the 
(SmAP2)7-protein (36 pmol/µl) were either injected alone or 25 µl of SmAP2-RBM 
(144 pmol/µl) and the (SmAP2)7 protein (72 pmol/µl) were mixed in a 2:1 molar ratio 
and incubated at 65°C for 10 min before injection. On-line detection was performed 
with a miniDawn Treos detector (Wyatt Technology Corp., Santa Barbara, CA).  
 
Supplementary Tables/ Figures 
Table S1.  Localization of the SmAP2-RBM present in 53 mRNAs enriched with 
SmAP2 (15). The coding sequence (ORF) and the first 100 nucleotides of the 3´UTR 
were used as input sequences for motif identification using the MEME tool 
(http://meme-suite.org/tools/meme). The table depicts the corresponding open 
reading frames (locus / column A; gene name / column B), the coding strand (column 
C), the motif start site (column D) relative to the first base of the start codon as 
depicted in column H, the p-value referring to the similarity of a given SmAP2-RBM 
with the SmAP2-cRBM (column E), and the corresponding SmAP2-RBM nucleotide 
sequences of the identified sites (column F). The function of the corresponding 
proteins (column G), the gene coordinates in the Sso genome (gene start/ column H; 
gene end / column I) and the gene length (column J) are indicated as well. The 
location of the motif within the corresponding gene, i.e. in the proximal (5´)-middle-
distal (3´) part, or in its 3´UTR is also denoted. The genes are sorted according to the 
p-values shown in column D.  
 
Table S2. Significance of the β-Galactosidase assays and qPCR assays using t-
test. The β-Galactosidase assays includes 3 biological samples each one assayed in 
6 technical repetitions. The values for the Miller units of each construct were 
compared to the control. The average, the standard deviation and the p-value 
derived from the t-test is depicted. The qPCR assays include 3 biological samples 
each one assayed in 3 technical repetitions. The values obtained for the ratio of 
lacS/16S of each construct were compared to the control. The average, the standard 
deviation and the p-value derived from the t-test is depicted.  
 
Figure S1. SmAP1 does not bind to the SmAP2-cRBM.  10 nM FAM-labelled 
SmAP2-cRBM (5´-FAM-GGAUGGAUAUUAGGAAAUG-3´) (purchased from 
Eurofins) was incubated with 0 nM (lane1), 50 nM (lane 2), 100 nM (lane 3), 200 nM 
(lane 4) , 400 nM (lane 5), 600 nM (lane 6), 800 nM (lane 7), 1000 nM (lane 8) and 
1500 nM (lane 9) of (SmAP1)7.  The molar ratios of (SmAP1)7 : SmAP2-cRBM are 





Figure S2. Genomic environment of Sso ORFs 1742, 2194 and 2912.  
A) The genome coordinates and the genomic context of the Sso 1742 gene, 
encoding a subunit of the terminal quinol oxidase (DoxD), are indicated. The 1742-RBM 
sequence 5´- GGAUGGAUAUUAGGUACUGGG-3´ at position 1580272-1580251 was 
identified using the MEME online tool (Table S1). The alignment with the SmAP2-
cRBM is depicted below.   
B) The genome coordinates and the genomic context of the Sso 2194 gene, 
encoding a putative thermopsine, are indicated. The 2194-RBM sequence 5´-
GGAGAUAUAGUAGGAUAG-3´ at position 2018033-2018054 was identified using 
the MEME online tool (Table S1). The alignment with the SmAP2-cRBM is depicted 
below.   
C) The genome coordinates and the genomic context of the Sso 2912 gene, 
encoding a sulfate adenylyltransferase (sat), are indicated. The 2912-RBM sequence 
5´ GGAAGUAUUGGGAGGAAUGAA-3´ at position 2663944-2663965  was identified 
using the MEME online tool (Table S1). The alignment with the SmAP2-cRBM is 
depicted below.   
 
Figure S3. Binding affinities of SmAP2 to SmAP2-cRBM and poly(U)15 
A) Dissociation constant (Kd) of fluorescently labelled SmAP2 for the SmAP2-cRBM 
as determined by microscale thermophoresis {Duhr, 2006 #253}. Increasing amounts 
of SmAP2-cRBM (A) were added to 30 nM NT-647 labelled (SmAP2)7 protein. The 
Kd was determined as described in Materials and Methods 
B) Dissociation constant (Kd) of fluorescently labelled SmAP2 for poly(U)15 as 
determined by microscale thermophoresis {Duhr, 2006 #253}. Increasing amounts of 
poly(U)15  were added to 30 nM NT-647 labelled (SmAP2)7 protein. The Kd was 
determined as described in Materials and Methods. 
C) Binding specificity of the SmAP2-cRBM:SmAP2-complex by using poly(U)15 as 
competitor RNA. Lane 1: SmAP2-cRBM alone. Lane 2: Complex of SmAP2-cRBM: 
(SmAP2)7 in a molar ratio of 1:20. Lane 3-8: SmAP2-cRBM and (SmAP2)7 were 
added in a molar ratio of 1:20 and poly(U)15 was added in increasing amounts as 
follows. Lane 3:  SmAP2-cRBM: poly(U)15 1:5, Lane 4:  SmAP2-cRBM: poly(U)15 
1:10, Lane 5:  SmAP2-cRBM: poly(U)15 1:20, Lane 6:  SmAP2-cRBM: poly(U)15 1:40, 
Lane 7: SmAP2-cRBM: poly(U)15 1:80, Lane 8:  SmAP2-cRBM: poly(U)15 1:100. The 
EMSA was carried out as described in Materials and Methods. 
 
Figure S4. SmAP2-SmAP2-RBM UV-cross-linking and MS analysis. MS/MS 
spectra of the two cross-linked peptides identified for SmAP2- SmAP2-RBM cross-
linking.  
A) MS/MS fragment spectra of peptide L24-K33 cross-linked to U-H2O, with a clear 
mass-shift indicating K25 as the cross-linked amino acid.  
B) MS/MS fragment spectra of peptide L34-R46 cross-linked to a uracil nucleotide 
lacking any b- and y-ions with a mass-shift that could indicate which amino acid is 
cross-linked. The cross-linked peptide sequence and its corresponding b- and y-type 
fragment ions are indicated at the top with the cross-linked amino acid highlighted in 
yellow. The b- and y-type fragment ion peaks with their corresponding m/z values are 
marked in the MS/MS spectrum and shown in red. Ions with a mass shift of #1 and #2 
correspond to the cross-linked nucleotides U´-H2O and U-H3PO4. U: Uracil; U´: Base 
of Uracil of 112.02 Da.  
Figure S5. Alignment and sub-domains of Sso SmAP1 and SmAP2.  
A) Alignment of the amino acid sequences SmAP1 (SSO6454) and SmAP2 
(SSO5410) using CLC sequence viewer software (http://download.cnet.com/CLC-
Sequence-Viewer/3000-2054_4-10439173.html). Conserved residues are marked in 
red. The residues involved in SmAP2-cRBM binding are indicated. K25 is marked with 
an arrow and the sub-sequence Leu34-Arg46 is marked with a yellow line. The 
positions of K25 and T40 are indicated by arrows.  The DxXxN and IRG motifs 
described as being involved in uracil binding in eukaryotic LSM-complexes (10) and 
in archaeal SmAPs (13, 14, 21, 22) are indicated by a blue line.  
B) Superposition of the putative uracil-binding pockets of Sso-SmAP1 and Sso-
SmAP2. The conserved residues forming the uracil-binding pocket as described for 
archaeal SmAP1 (13, 14, 21, 22) are depicted in blue for Sso-SmAP1. The 
corresponding residues in Sso-SmAP2 are superimposed and shown in magenta. 
 
Figure S6. Analytical size-exclusion chromatography.  The experiment was 
performed as described in Supporting Information. The corresponding graphs 
obtained with the SmAP2-RBM, (SmAP2)7 and with the (SmAP2)7 : SmAP2-RBM 
complex are shown superimposed.  
 
Figure S7. Regulatory function of the SmAP2-cRBM motif.  
A) Schematic depiction of the SSV-1 derived Sso-shuttle plasmid pMJ05, in which 
the lacS gene containing its authentic 3´UTR is preceded by an tf55α-promoter. In 
the lacS 2194-RBM-3´UTR construct, the 2194-RBM identified in the 3´UTR of the 
putative thermopsine gene (SSO2194) was transplanted to the 3´UTR of the lacS 
gene, 14 nt downstream of the G of the TAG stop codon.   
B) Schematic depiction of the SSV-1 derived Sso-shuttle plasmid pMJO5, in which 
the lacS 3´UTR was replaced by the 2194-3´UTR (lacS 2194-3´UTR). In the lacS 
∆2194-RBM-2194-3’UTR construct the 2194-RBM 5´-
GGAGATATAGTAGGTATAGTA-3´ was replaced by the sequence 5´-
TTCTGGCCCACCATACCATCGC-3´.  
C) ß-galactosidase activities (top panel) and lacS mRNA steady state levels (bottom 
panel obtained with the Sso strain PH1-16 harbouring the constructs containing the 
lacS 3´UTR (pMJ05- tf55α-lacS-3’UTR; grey bars) and the 2194-RBM inserted in the 
lacS 3´UTR (pMJ05- tf55α-lacS-2194-RBM-lacS-3’UTR; red bars), respectively. The 
ß-galactosidase activities and the lacS mRNA levels were determined as described in 
Materials and Methods. Each experiment was performed with three biological (ß-gal. 
assays and lacS mRNA levels) and six (ß-gal. assays) and three (lacS mRNA levels) 
technical replicates of the respective strains. The error bars are derived from 
biological and technical replicates. 
D) ß-galactosidase activities (top panel) and lacS mRNA steady state levels (bottom 
panel) obtained with the Sso strain PH1-16 harbouring the constructs containing the 
2194-3´UTR abutted to the lacS gene (pMJ05- tf55α-lacS-2194-3’UTR; red bars) and 
the ∆2194-RBM-2194-3’UTR (pMJ05-tf55α-∆2194-RBM-2194-3’UTR; blue bars), 
respectively. The ß-galactosidase activities and the lacS mRNA levels were 
determined as described in Materials and Methods. Each experiment was performed 
with three biological (ß-gal. assays and lacS mRNA levels) and six (ß-gal. assays) 
and three (lacS mRNA levels) technical replicates of the respective strains. The error 
bars are derived from biological and technical replicates. 
 
 
Figure S8. Activity of the ara promoter in the presence of sucrose and 
arabinose. 
A) LacS mRNA levels and β-Galactosidase activity in sucrose and arabinose. The 
Sso strain PH1-16(pMJ05-Ara/ lacS-3’UTR) was grown to an OD600 of 0.4 in Brock´s 
medium containing 20 % sucrose or 20 % arabinose. Total RNA isolation and reverse 
transcription was performed as described in Materials and Methods. The lacS mRNA 
levels were determined using qPCR as described in Materials and Methods. The β-
Galactosidase activity was determined as described in Materials and Methods.   
B) Decrease of lacS mRNA levels after promoter shut-off upon shift to sucrose-
containing medium.  The Sso strains PH1-16(pMJ05-Ara-lacS-3’UTR) and PH1-
16(pMJ05-Ara-lacS-2194-RBM-3’UTR) were grown in Brock’s medium at 75°C 
containing 0.2% arabinose to an OD600 of 0.5. The cells were pelleted and 
resuspended in the same volume of Brock’s medium containing 0.2% sucrose pre-
warmed to 75°C (= 0 min). After 2h and 4h, 10 ml of the cultures were withdrawn, 
total RNA was isolated and cDNA was generated as described in Materials and 
Methods. The lacS mRNA levels at the different time points after promoter shut-off 
were determined using total RNA from Sso expressing either lacS with the authentic 
lacS-3´UTR (lacS-3´UTR / grey bar) or lacS bearing the 2194-RBM in the lacS-3’UTR 
(lacS 2194-RBM-3’UTR / red bar). The lacS levels were normalized to 16S rRNA. 
The lacS levels at time 0 were set to 100%.  
 
Figure S9. Similarities of the SmAP2-cRBM and known RNA binding motifs 
using TomTom {Gupta, 2007 #293}. The SmAP2-cRBM identified with the MEME 
tool {Bailey, 2009 #291} was submitted to TomTom {Gupta, 2007 #293} to find similar 
motifs in published libraries. As motif database the settings RNA (DNA-encoded) and 
Ray2013 all species was selected. The alignment of the best hits are depicted 
showing the part with similarities to the SmAP2-cRBM.   
 
Figure S1 
  0     5     10       20     40     60      80    100    150    
SmAP2-cRBM 
(SmAP1)7: SmAP2-cRBM molar ratio 
A  
1742-RBM:                    GGAUGGAUAUUAGGUACUGGG 
              












2016662 2017993 2018033 2018054 
2194-3‘UTR 
B  
2194-RBM:                    GGA- GAUAUAGUAGGAUA-G 
              
SmAP2-cRBM:               GGAUGGAUAU--UAGGAAAUG  
  
C  
2912-RBM:                    GGAAG--UAUUGGGAGGAAUGAA 
              












































 0         0         5       10      20      40      80     100     



















































    







































































Locus Name Strand Motif start site p -value Sites Function Gene Start Gene end Gene lenght Motif localisation
sso1742 doxD + 606 2.42e-9 GGATGGATATTAGGTACTGGG Terminal quinol oxidase, subunit (DoxD) 1580877 1580326 552 3' UTR 
sso3038 + 58 2.42e-9 GGATGGATATTAGGTACTGGG Hypothetical 2788619 2789539 921 5' 
sso1741 doxA + 58 2.42e-9 GGATGGATATTAGGTACTGGG Terminal quinol oxidase, subunit II (DoxA) 1580329 1579814 516 5' 
sso3055 + 1747 1.29e-8 GGAAGGATAGTAGAAAAGGGA Maltose ABC transporter, ATP-binding protein 2811463 2809610 1854 3'
sso3039 + 129 4.58e-8 GGAGAGAAATGAGGATAGGTA predicted bile acid beta-glucosidase 2792033 2789622 2412 5' 
sso3077 + 12 1.40e-7 GGAGAGGCTTGAGGCTAGGAA Transposase 2832250 2832648 399 5' 
sso2913 + 78 4.38e-7 GGAAGTATTGGGAGGAATGAA Hypothetical 2663867 2664172 306 5' 
sso2912 sat + 1299 4.38e-7 GGAAGTATTGGGAGGAATGAA Sulfate adenylyltransferase 2662646 2663866 1221 3'UTR
sso3045 + 694 1.07e-6 GGTAGGATAGTGGAGGAGGGT ABC transporter, ATP binding protein 2797270 2796467 804 3'
sso3048 + 655 1.07e-6 GGATGGATAATGGGAATGAGA peptide/nickel transport system permease protein; Quorum sensing 2800256 2799228 1029 middle
sso3054 + 286 1.07e-6 GAAAGGATATTAGGGGAGGCA Oxidoreductase 2808423 2809529 1107 5' 
Sso3043 - 642 1.21e-6 GGATTTGTATTAGGGTATGTG peptide/nickel transport system substrate-binding protein; Quorum sensing 2796309 2794177 2133 middle
sso3051 malA + 222 1.36e-6 GGATAGAAAGAGGAAAAGGTA Alpha-glucosidase 2804870 2802789 2082 5' 
sso3032 + 1663 1.53e-6 GGAGAAGAAGGAGGAAATGCC Beta-xylosidase 2782593 2780329 2265 3'
sso11972 + 174 1.53e-6 AGTTGAAAAGGGGGAGAGGAG sec-independent protein translocase protein TatA; protein export 2860119 2860394 276 middle
sso3052 + 411 1.93e-6 GGGTGGATTTAGGGCTAAGGT GDSL-like Lipase/Acylhydrolase 2805291 2805923 633 middle
sso8195 - 24 2.17e-6 GGAAGAGATAAAGGAAGGGAG Third part of one of two inversely orientated ORFs in ISC1043 1341626 1341778 153 5' 
sso3042 dhg-2 + 329 2.42e-6 AGAGAGGATGTGGGAAATGTC Glucose 1-dehydrogenase 2792972 2794132 1161 5' 
sso0117 - 434 3.02e-6 GGATTGAAAAAAGGATATGAG conserved hypothetical protein 96562 96149 414 3'
sso3036 gusB - 384 3.36e-6 GGTAAGTTATAGGGGGATGGC Beta-glucuronidase (GusB) 2787694 2785982 1713 5' 
sso11909 + 81 3.36e-6 GGGTAGGCTTAGGGGTAAGAA Transposase 2832735 2832917 183 middle
sso2508 acaB-6 + 1094 3.74e-6 GGTGGAGTAGAAGGCACAGTG Acetyl-CoA c-acetyltransferase (Acetoacetyl-CoA thiolase) 2276632 2277774 1143 3'
sso3035 dapA-2 + 187 3.74e-6 AGAAGAGCATTAAGTAAGGGC Dihydrodipicolinate synthase 2784953 2785861 909 5' 
sso2292 + 991 4.16e-6 GAATGGATATTGGGGCTGGGG putative amino acid transporter 2102240 2103778 1539 3'
sso2914 + 368 4.16e-6 AGATAGGTTTGGAGAAGTGGA putative permease 2664169 2665023 855 middle
sso3041 + 324 4.16e-6 GGATAGGTACTGGGCTGGGAC gluconolaconase 2792118 2792975 858 middle
sso10674 - 171 4.61e-6 AGCTGGAGTTTAGGGAATGAC Second ORF in transposon ISC1359;SSO10674;ortholog 2338953 2339186 234 3'
sso2911 csyH + 396 5.11e-6 GGATGGAATGGAAGCTTGGAT 3'-phosphoadenosine 5'-phosphosulfate sulfotransferase (PAPS reductase) 2662545 2661826 720 middle
sso0915 + 207 5.11e-6 GGTAGAGATTGAAGGTAAGAA chromatin protein Cren7 778742 779071 330 middle
sso3047 + 520 5.11e-6 GGTTGGGCATGGGGTGCTAGG ABC transporter, permease 2799235 2798255 981 middle
sso3053 + 829 5.11e-6 GGTGGAACTGGAAGTACTGGA Maltose ABC transporter, maltose binding protein 2808286 2806121 2166 middle
sso2908 cysG + 481 6.91e-6 GGCAGGAGATTAGAGGAGGTG Uroporphyrin-III C-methyltransferase (Siroheme synthase) 2659944 2659249 696 3'
sso2194 + 1372 8.39e-6 GGAGATATAGTAGGTATAGTA Thermopsine precursor related protein 2016662 2017993 1332 3'UTR
sso3049 + 1008 9.24e-6 AAATGGAAAAGAGGGTATGAA putative dehydrogenase 2800800 2801915 1116 3'
sso2485 - 55 9.24e-6 GGGTAAATATTGGGCAATAGC oligosaccharide biosynthesis protein Al 2257112 2256156 957 5' 
sso0281 - 202 1.02e-5 AGATGAGTTTAAGGCTGTGTA tRNA-intron endonuclease, archaea type 238896 238363 534 middle
sso1948 + 733 1.02e-5 GGGGAGGAAATGAGATATGTG putative bile acid beta-glucosidase 1767983 1765998 1986 middle
sso2089 + 264 1.12e-5 GCTAGGGATTGAGGTAAAGGA transcriptional activator, TenA family   1903080 1902460 909 5' 
sso1676 + 951 1.22e-5 GGTCGTAAAAAAGGAAATGGA Hypothetical 1529268 1530953 1686 middle
sso3037 + 375 1.22e-5 GGAAGTTCTGTGGAGTAGGAA Hypothetical 2787812 2788291 480 3'
sso3050 + 261 1.22e-5 GGTTGAAATTGAGGTAATAAC Xylose isomerase 2802084 2802084 714 middle
sso3090 + 925 1.34e-5 AGCAAGAAATTAAGAGAGGGA Hypothetical 2844180 2845145 966 3'
sso3034 + 59 1.60e-5 AGAGGGTAAGTAGGTTTGGGT Xylose isomerase 2784903 2784328 576 5' 
sso3085 + 73 1.75e-5 GGATTTATTTTGGGTTGGGCA Transporter 2840662 2839433 1230 5' 
sso3046 + 594 2.47e-5 GAAAATACAGAAGGAAAAGGA ABC transporter, ATP binding protein 2798258 2797263 996 middle
sso1817 cysA-2 + 685 2.91e-5 AGAAGATTAGTAGAGAATGTA Thiosulfate sulfurtransferase 1649681 1648800 882 3'
sso1536 + 450 3.16e-5 GGATAAGTTAACGGATAGGAA putative DNA binding protein   1388376 1388376 648 3'
sso3029 + 436 3.16e-5 AGTTGTTTTGTAGGCACAGGG Xylose isomerase 2777610 2778416 807 middle
sso0175 + 26 3.71e-5 GGAGTGATATTAAAATGGGTA Peptidyl-tRNA hydrolase;pth;ortholog 146727 146365 363 5' 
sso1905 - 437 5.88e-5 GGTAAAAGATTGAGATGAGAG Allantoin permease 1724466 1723000 1467 5' 
sso2476 - 762 1.18e-4 GAATGTGGATAAAGGTATAGG Na+/proline symporter 2247725 2249242 1518 middle
sso0118 + 25 1.18e-4 GGGTATAAATTAAAAAAGAGA Hypothetical 97032 96568 465 5' 
sso0829 + 454 1.53e-4 GGTGGAAAAATAAGTATAGAT FkbM family methyltransferase 710062 710967 906 middle
Table S2
ß-Gal Assay
Sample Average Standard deviation t test/pvalue
lacS 3'UTR 10214 361
lacS 2194-RBM- 3'UTR 7910 488 0,0004
lacS 2912-RBM-3'UTR 7912 508 0,0037
lacS 1742-RBM-3'UTR 6228 594 0,0013
lacs 2194-3'UTR 3211 159
lacs ∆2194-RBM-2194-3'UTR 5524 185 0,0001
qPCR
Sample Average Standard deviation t test/pvalue
lacS 3'UTR 0,61 0,04
lacS 2194-RBM- 3'UTR 0,39 0,03 0.0270
lacS 2912-RBM-3'UTR 0,36 0,01 0.0165
lacS 1742-RBM-3'UTR 0,29 0,03 0.0135
lacs 2194-3'UTR 0,14 0,04
lacs ∆2194-RBM-2194-3'UTR 0,34 0,03 0.0282
